The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Abstract The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approve...

Full description

Bibliographic Details
Main Authors: Brian I. Rini, Dena Battle, Robert A. Figlin, Daniel J. George, Hans Hammers, Tom Hutson, Eric Jonasch, Richard W. Joseph, David F. McDermott, Robert J. Motzer, Sumanta K. Pal, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood, Michael B. Atkins
Format: Article
Language:English
Published: BMJ Publishing Group 2019-12-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Guidelines
Immunotherapy
Renal cell carcinoma (RCC)
Kidney cancer
Immune checkpoint inhibitor (ICI)
Online Access:http://link.springer.com/article/10.1186/s40425-019-0813-8

Internet

http://link.springer.com/article/10.1186/s40425-019-0813-8

Similar Items